Use in pregnancy

Lumeva · Episodic migraine

MI-2026-0295UrgentArchivedWithin SLASafety

FAFatima Al-SayedMedical Information Lead

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 14 Jan 2026, 11:35 UTC
Channel: MSL
Requestor type: Payer
Country / region / team: Australia · Asia-Pacific · MI APAC
Category: Safety
Response type: Standard response
Owner: FAFatima Al-Sayed
Due: 16 Jan 2026, 11:35 UTC
Responded: 15 Jan 2026, 16:35 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-LMV-009 · Use in pregnancy and lactation (v2)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
Closed
12Archived

Current stageArchivedDemo action — not persisted

SLA

Urgent: 48 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

Elapsed

29 h

to response

Remaining

19 h

60%

Timeline

14 Jan 2026, 11:35 UTC
Received via MSL
Payer · Australia
14 Jan 2026, 11:35 UTC
Triage and assignment
Urgency Urgent · assigned to MI APAC
15 Jan 2026, 16:35 UTC
Response sent
Standard response · quality review not required
16 Jan 2026, 11:35 UTC
SLA due (48 h)

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 14 Jan 2026 · hourly sync.